GadoteratMeglumin

Gadoterate meglumine is a gadolinium-based contrast agent used to enhance magnetic resonance imaging (MRI). It is administered intravenously to improve visualization of tissues, vascular structures, and the integrity of the blood-brain barrier, aiding the detection and characterization of tumors, inflammatory lesions, and vascular abnormalities.

Chemically, gadoterate meglumine is a gadolinium(III) complex in which the Gd3+ ion is bound by the macrocyclic chelator DOTA and balanced by meglumine counterions. The macrocyclic structure provides high kinetic and thermodynamic stability, contributing to a relatively favorable safety profile compared with some linear gadolinium agents.

Administration and dosage typically involve a single intravenous injection of 0.1 mmol/kg body weight, delivered as a rapid bolus or slower infusion according to the imaging protocol, followed by a saline flush. The timing of image acquisition depends on the intended diagnostic purpose.

Adverse effects are usually mild and transient, such as headaches, nausea, or a sensation of warmth at the injection site. Severe allergic reactions are rare. Gadolinium-based contrast agents, including gadoterate meglumine, have been associated with nephrogenic systemic fibrosis in people with severely reduced kidney function; macrocyclic agents generally carry a lower risk. Ongoing concerns about gadolinium deposition with repeated exposure have led regulators to advise using the lowest effective dose and to evaluate the necessity of contrast on an individual basis, particularly in patients with renal impairment or pregnancy.

Availability and branding vary by region; gadoterate meglumine is marketed under brand names such as Dotarem, with generic formulations also available in many markets.